Oxidative stress and antioxidative parameters and metal ion content in patients with fibromyalgia syndrome: Implications in the pathogenesis of disease

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.79, 2013, Pages

  Fatima, Ghizal ^a   Das, Siddharth Kumar ^a   Mahdi, Abbas ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Antioxidative parameters; Fibromyalgia syndrome; Metal ions; Oxidative stress

Indexed keywords

ALUMINUM; INTERLEUKIN 1; INTERLEUKIN 6; LEAD; MAGNESIUM; MALONALDEHYDE; METAL ION; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; ZINC;

COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA FRAGMENTATION; FIBROMYALGIA; HEAVY METAL POISONING; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 84892470444     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. WOLFE F, SMYTHE HA, YUNUS MB et al.: The American College of Rheumatology Criteria for the classification of fibromyalgia. Arthritis and Rheum 1990; 33: 160-72.
2. WOLFE F, CLAUW DJ, FITZCHARLES MA et al.: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62: 600- 10.
3. SALAFFI F, SARZI-PUTTINI P: Old and new criteria for the classification and diagnosis of fibromyalgia: comparison and evaluation. Clin Exp Rheumatol 2012; 30: 3-9.
4. BARTELS EM, DREYER L, JACOBSEN S, JESPERSEN A: Fibromyalgia, diagnosis and prevalence. Are gender differences explainable? Ugeskr Laeger 2009; 171: 3588-92.
5. BRANCO JC, BANNWARTH B, FAILDE I et al.: Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010; 39: 448-53.
6. LAWRENCE RC, FELSON DT, HELMICK CG et al.: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 2008; 58: 26-35.
7. OZGOCMEN S, OZYURT H, SOGUT S et al.: Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide. Rheumatol Int 2006; 26: 585-97.
8. PIECZENIK SR, NEUSTADT J: Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007; 83: 84-92.
9. VALKO M, LEIBFRITZ D, MONCOL J et al.: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem 2007; 39: 44-84.
10. ESTERBAUER H, SCHAUR RJ, ZOLLNER H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol 1991; 11: 81-128.
11. WANG ZQ, PORRECA F, CUZZOCREA S et al.: A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther 2004; 309: 869-78.
12. VECCHIET J, CIPOLLONE F, FALASCA K et al.: Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 2003; 335: 151-4.
13. KEENOY B, MOORKENS G, VERTOMMEN J, DE L I: Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci 2001; 68: 2037-49.
14. CORDERO MD: Oxidative stress in fibromyalgia: pathophysiology and clinical implications. (in Spanish) Reumatol Clin 2011; 7: 281-3.
15. CORDERO MD, DíAZ-PARRADO E, CARRIóN AM et al.: Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia?. Antioxid Redox Signal 2013; 18: 800-7.
16. NEYAL M, YIMENICIOGLU F, AYDENIZ A et al.: Plasma nitrite levels, total antioxidant status, total oxidant status, and oxidative stress index in patients with tension-type headache and fibromyalgia. Clin Neurol Neurosurg 2012; 12: 453-2.
17. de ZWART LL, MEERMAN JN, COMMANDEUR JM et al.: Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med 1999; 26: 202-26.
18. OZGOCMEN S, OZYURT H, SOGUT S et al.: Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 2006; 26: 598-603.
19. ALTINDAG O, CELIK H: Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep 2006; 11: 131- 5.
20. FASSBENDER HG, WEGNER K: Morphology and pathogenesis of soft tissue rheumatism. Z Rheumaforsch 1973; 32: 355-74.
21. LUND N, BENGTSSON A, THORBORG P: Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol 1986; 15: 165-73.
22. BENGTSSON A, HENRIKSSON KG, LARSSON J: Reduced high energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 1986; 15: 1-6.
23. SENDUR OF, TURAN Y, TASTABAN E, YENISEY C, SERTER M: Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int 2009; 29: 629-33.
24. CORDERO MD, DEMIGUEL M, MORENO FERNáNDEZ AM et al.: Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 2010; 12: R17.
25. CORDERO MD, MIGUEL M, MORENOFERNáNDEZ AM: Mitochondrial dysfunction in fibromyalgia and its implication in the pathogenesis of disease. Med Clin (Barc). 2011; 136: 252-6.
26. MENZIES V, LYON DE: Integrated review of the association of cytokines with fibromyalgia and fibromyalgia core symptoms. Biol Res Nurs 2010; 11: 387-94.
27. FULLE S, MECOCCI P, FANO G et al.: Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 2000; 29: 1252-9.
28. KIGWELL BA: Nitric oxide-mediated metabolic regulation during exercise: effect of training in health and cardiovascular disease. FASEB J 2000; 14: 1685-96.
29. AKYOL O, ZOROGLU SS, ARMUTCU F et al.: Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 2004; 18: 377-90.
30. CEPINSKAS G, RUI T, KVIETYS PR: Interaction between reactive oxygen metabolites and nitric oxide in oxidant tolerance. Free Radic Biol Med 2002; 33: 433-40.
31. LARSON AA, GIOVENGO SL, RUSSELL IJ et al.: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000; 87: 201-11.
32. SPROTT H, SALEMI S, GAY RE et al.: Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres. Ann Rheum Dis 2004; 63: 245-51.
33. YUNUS MB, KALYAN-RAMAN UP, KALYANRAMAN K et al.: Pathologic changes in muscle in primary fibromyalgia syndrome. Am J Med 1986; 81: 38-42.
34. HALLIWELL B, GUTTERIDGE JC: The definition and measurement of antioxidants in biological systems. Free Radic Biol Med 1995; 18: 125-6.
35. EREL O: A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-9.
36. HALLIWELL B: Free radicals, antioxidants and human disease: curiosity, cause or consequence. Lancet 1994; 344: 721-4.
37. FRANCO AA, ODOM RS, RANDO TA: Regulation of antioxidant enzyme gene expression in response to oxidative stress and during differentiation of mouse skeletal muscle. Free Radic Biol Med 1999; 27: 1122-32.
38. LUND N, BENGTSSON A, THORBORG P: Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol 1986; 15: 165-73.
39. SCHEIBMEIR HD, CHRISTENSEN K, WHITAKER SH, JEGAETHESAN J, CLANCY R, PIERCE JD: A review of free radicals and antioxidants for critical care nurses. Intensive Crit Care Nurs 2005; 21: 24-8.
40. ALI M: The cause of fibromyalgia: the respiratory- to-fermentative shift (the DysOx State) in ATP production. J Integr Med 2003; 8: 135-40.
41. BRAMWELL B, FERGUSON S, SCARLETT N, MACINTOSH A: The use of ascorbigen in the treatment of fibromyalgia patients: a preliminary trial. Altern Med Rev 2000; 5: 455-62.
42. GABY ALAN R: Intravenous nutrient therapy: the "Myers' cocktail". ("Myers' Cocktail"). Altern Med Rev 2002; 7: 389-403.
43. LISTER RE: An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res 2002; 30: 195-9.
44. FU X, JI R, DAM J: Antifatigue effect of coenzyme Q10 in mice. J Med Food 2010; 13: 211-5.
45. MIZUNO K, TANAKA M, NOZAKI S et al.: Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition 2008; 24: 293-9.
46. CASO G, KELLY P, McNURLAN MA, LAWSON WE: Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99: 1409-12.
47. JUNG HJ, PARK EH, LIM CJ: Evaluation of anti-angiogenic, anti-inflammatory and antinociceptive activity of coenzyme Q(10) in experimental animals. J Pharm Pharmacol 2009; 61: 1391-5.
48. SCHMELZER C, LINDNER I, RIMBACH G et al.: Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 2008; 32: 179-83.
49. MENZIES V, LYON DE: Integrated review of the association of cytokines with fibromyalgia and fibromyalgia core symptoms. Biol Res Nurs 2010;11: 387-94.
50. KELLER JN, MATTSON MP: Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci 1998; 9: 105-16.
51. WANG ZQ, PORRECA F, CUZZOCREA S et al.: A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther 2004; 309: 869-78.
52. HOLTON KF, TAREN DL, THOMSON CA, BENNETT RM, JONES KD: The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 10-7.
53. DING W, ZHU Q: Metabolism of aluminum in rats. J Chem Res Toxicol 1997; 31: 338-41.
54. ANDREWS GK: Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochemical Pharmacology 2000; 59: 95-104.
55. FOURNIé GJ, MAS M, CAUTAIN B et al.: Induction of autoimmunity through bystander effects: Lessons from immunological disorders induced by heavy metals. J Autoimmun 2001; 16: 319-26.
56. PERNAMBUCO AP, SCHETINO LP, ALVIM CC et al.: Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol 2013 Sep 10. Epub ahead of print.
57. ROSBORG I, HYLLéN E, LIDBECK J, NIHLGåRD B, GERHARDSSON L: Trace element pattern in patients with fibromyalgia. Sci Total Environ 2007; 385: 20-7.
58. EISINGER J, PLANTAMURA A, MARIE PA, AYAVOU T: Selenium and magnesium status in fibromyalgia. Magnes Res 1994; 7: 285- 258.
59. BAZZICHI L, GIANNACCINI G, BETTI L et al.: ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia. Clin Biochem 2008; 41: 1084-90.
60. SAKARYA ST, AKYOL Y, BEDIR A, CANTURK F: The relationship between serum antioxidant vitamins, magnesium levels, and clinical parameters in patients with primary fibromyalgia syndrome. Clin Rheumatol 2011; 30: 1039-43.
61. SENDUR F, TASTABAN E, TURAN Y et al.: The relationship between serum trace element levels and clinical parameters in patients with fibromyalgia. Rheumatol Int 2008; 28: 1117-21.
62. LAWRENCE DA, KIM D: Central / peripheral nervous system and immune responses. Toxicology 2000; 142: 189-201.
63. PIECZENIK SR, NEUSTADT J: Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007; 83: 84-92.